Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015

BACKGROUND: The addition of bevacizumab to cytotoxic agents prolongs survival in patients with nonsquamous non-small cell lung cancer (NSCLC). To date, there is no evidence to suggest that treatment with a cytotoxic agent plus bevacizumab is more effective than a cytotoxic agent alone for nonsquamou...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozuki, Toshiyuki, Nogami, Naoyuki, Kitajima, Hiromoto, Iwasawa, Shunichiro, Sakaida, Emiko, Takiguchi, Yuichi, Ikeda, Satoshi, Yoshida, Masahiro, Kato, Terufumi, Miyamoto, Shingo, Sakamaki, Kentaro, Shinkai, Tetsu, Watanabe, Koshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866483/
https://www.ncbi.nlm.nih.gov/pubmed/27177035
http://dx.doi.org/10.1186/s12885-016-2338-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866483/
https://www.ncbi.nlm.nih.gov/pubmed/27177035
http://dx.doi.org/10.1186/s12885-016-2338-6

Ejemplares similares